CMIC Group Launches New CDMO Business in Japan
CMIC Bio will offer contract development and manufacturing organization services for biopharmaceutical drug substance.
CMIC Group, a contract research organization located in Japan, announced on July 22, 2020 that it is establishing CMIC Bio, a subsidiary that will offer contract development and manufacturing organization services for biopharmaceutical drug substance.
According to a company press release, CMIC Bio’s single-use facility for process development and GMP manufacturing of antibody drugs using mammalian cell lines in Shizuoka, Japan, will be in full-scale operation starting in October 2020.
“At CMIC Bio, we have personnel with abundant experience at pharmaceutical companies and have strengths in GMP API manufacturing bases in Japan to assist in accelerating the development speed of biopharmaceuticals,” said Hiroshi Kosaku, president of CMIC Pharmaceutical Sciences, in the press release. “CMIC Group will provide end to end solutions from non-clinical testing, running clinical trial, GMP manufacturing of biopharmaceuticals to the commercialization and post market.”
